ArticleFrontiers in oncology2026
Persistent dysbiosis of intestinal and oral microbiota after neoadjuvant radiotherapy for rectal cancer: Implications for surgery and microbiome intervention.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular pathways linking the gut microbiome to antitumor immunity.Trends in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant radiotherapy represents a conventional approach for managing locally advanced rectal carcinoma. Although this regimen has many benefits, radiation injury is associated with intestinal mucosal injury and gut microbiota dysbiosis. The long-term dynamics of inflammation and microbial recovery, including oral microbiota alterations, remain unclear. Methods: Intestinal mucosal specimens were obtained from patients with rectal cancer who underwent surgical treatment without radiotherapy or at predetermined time intervals (4 ± 1 weeks, 8 ± 1 weeks and 12 ± 1 weeks) after radiotherapy. The levels of TNF-α, IL-4 and IL-6 in the intestinal mucosa were determined using ELISA. Meanwhile, the intestinal mucosa and saliva of 18 recruited rectal cancer patients were subjected to 16S rRNA gene sequencing (radiotherapy group, n=9; non-radiotherapy group, n=9) for analysis of the gut and oral microbial communities. Results: Mucosal IL-4 levels were still significantly elevated at 12 weeks post-radiotherapy with respect to the non-radiotherapy group (p<0.05), while TNF-α and IL-6 were back at baseline levels. The gut microbiota composition of radiotherapy patients differed from that of non-radiotherapy patients, with a significant reduction in Chao1 diversity index (p<0.01) and distinct β-diversity clustering (ANOSIM R = 0.614, p=0.001). These differences were still present at 12 weeks post radiotherapy. The oral microbiota changes were limited, with only a few taxa that showed significant differences (ANOSIM R = 0.38, p=0.009). Conclusion: Neoadjuvant radiotherapy is associated with persistent intestinal mucosa inflammation and prolonged disruption of gut microbiota and this dysbiosis does not fully normalize within 12 weeks after treatment. Changes in oral microbiota appeared less pronounced. These findings provide the biological context for understanding intestinal recovery after radiotherapy and indicate that more studies are needed to direct future efforts towards the peri-operative manipulation of gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.